3 CBD Stocks to Buy Ahead of the 3rd-Green Wave Rebound

The legalization of CBD-infused hemp products in the U.S. markets has opened doors for the explosive CBD edibles market. This emerging market and touted as the next big thing and will have a value of $2.8 Billion in the next 4 years. Many cannabis companies will cash in on the opportunity, allowing investors to profit. 

HempFusion Wellness Inc. (TSX:CBD.U) (OTC: CBDHF) (“HempFusion” or the “Company”), a leading health and wellness Company offering premium probiotic supplements and products containing CBD, is pleased to announce it has entered into a Purchase Agreement (as defined below) to acquire 100% interest in APCNA Holdings LLC (“Apothecanna”). Established in 2009, Apothecanna pioneered cannabis-powered body care and topicals, and was the first topicals brand to expand nationally and obtain a Federal Trademark. Focused on the premium recovery, pharmacy, and spa segments, Apothecanna has established itself as an industry leader in the development of innovative, all-natural CBD products.

Apothecanna is an established brand in the premium CBD topicals space with significant distribution in the North American market, most notably though CVS and 7th Sense. The company also has access to the Canadian marketplace though a strategic business relationship, giving it significant market share in the Canadian topicals space (#1 topical in 2020 on the OCS).

American Premium Water Corporation (OTC: HIPH) recently announced it has come to terms on the acquisition of licenses to distribute and retail hemp cannabinoids in the State of New York as part of the State’s program to establish quality control standards on the industry. 

The Company expects to close the transaction by the end of the 1st half 2021. (Disclosure: The Company acquired these licenses from a New York entity that was owned by CEO, Ryan Fishoff. The proposed consideration for the licenses is nominal.) 

Goldman Small Cap Research, a sponsored research provider focused on microcap stocks, has issued a new research update. This update highlights the impact of the Company recent developments, including its joint venture with Cali Bear (  

In the sponsored research update, analyst Rob Goldman affirms his price target of $0.0425 and his investment thesis, noting that the news reflects a milestone event that is wide-reaching for the Company in terms of revenue, cross-selling opportunities, and a reach into new markets. 

Green Globe International Inc. (OTC: GGII) recently announced that on or about March 22, 2021, as a result of a private sale of 100 Series A Preferred Shares of GGII, control of GGII passed to The Hempacco Co., Inc. (“Hempacco”).

A new board of directors of GGII, under the leadership of Hempacco’s visionary CEO, Sandro Piancone, was appointed, and GGII applied to OTC Markets Group, Inc. for access to its information and disclosure system in order to be able to file missing reports and add further information on the new ownership group. This process can take three to four weeks to complete.

Hempacco’s business model is Disrupting Tobacco™ with consumer goods in the form of herb cigarettes, CBD, CBG, Hemp Cigarettes, and other plant-based natural smokables.

Once GGII is current with its OTC Markets filing obligations, it plans to pursue a potential merger or combination of operations with Hempacco. No definitive agreements have been signed between GGII and Hempacco, and there is no guarantee that such agreements will be entered into or that a combination will occur.



Please enter your comment!
Please enter your name here